Medpage Today on MSN13d
HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast CancerA HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...
Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.
New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...
Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...
Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.
WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM Independent findings support ...
HER2+转移性乳腺癌患者的长期生存或与调节性T细胞活性相关。HER2阳性（HER2+）乳腺癌约占全部乳腺癌的15%-20%，患者预后往往较差[1]。尽管曲妥珠单抗联合化疗能够显著改善患者的疗效和延长生存期（OS），但大多数患者会发生疾病进展[2,3 ...
A multicenter phase II trial has demonstrated that a combination of pyrotinib and fulvestrant offers significant antitumor ...
enables the identification of patients who are HER2-high, intermediate or low and therefore suitable for treatment with HER2-antibody drug conjugates (ADCs). The poster reports on a study in 16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback